Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement


NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 — Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, and XL-protein, a privately owned biopharmaceutical company, announced today that they have entered into a License, Development and Commercialization Agreement. This partnership is focused on developing a second generation, longer acting version of Coversin.

Subscribe to get the latest news